Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melatonin receptor type 1B (MT2, encoded by the MTNR1B gene) is a high-affinity G protein-coupled receptor (GPCR) that mediates the physiological actions of melatonin, a hormone primarily secreted by the pineal gland in a circadian pattern. MT2 is predominantly expressed in the retina, brain (specifically the suprachiasmatic nucleus), and peripheral tissues such as pancreatic islets. It plays a critical role in regulating circadian rhythms, sleep-wake cycles, visual processing, and glucose homeostasis. Pharmacological targeting of MT2, typically via non-selective MT1/MT2 agonists like ramelteon, agomelatine, and tasimelteon, is widely utilized to treat insomnia, circadian rhythm sleep disorders, and major depressive disorder. Additionally, genetic variations in MTNR1B (such as the rs10830963 variant) are strongly linked to altered insulin secretion and an increased risk of type 2 diabetes, highlighting its emerging significance in metabolic health and personalized medicine.
Agonist of melatonin receptors MT1 and MT2, modulating circadian rhythms and sleep-wake cycles.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Melatonin receptor type 1B (MT2).